NCT00461903View on ClinicalTrials.gov

Efficacy of Perindopril to Prevent Recurrence of Atrial Fibrillation in Patients With Essential Hypertension

PHASE3CompletedINTERVENTIONAL

Enrollment

316

Participants

Timeline

Start Date

December 31, 2007

Primary Completion Date

September 30, 2015

Study Completion Date

September 30, 2015

Conditions

Essential HypertensionAtrial Fibrillation

Interventions

DRUG

Perindopril

Perindopril 4 mg or matching placebo , 1 tablet administrated once daily for the first 2 weeks. If tolarable, dosage increased to 8mg/day until the end of the study (

Trial Locations (1)

H1T 1C8

Montreal Heart Institute, Montreal

All Listed Sponsors

collaborator

Servier

INDUSTRY

lead

Montreal Heart Institute

OTHER

NCT00461903 - Efficacy of Perindopril to Prevent Recurrence of Atrial Fibrillation in Patients With Essential Hypertension | Biotech Hunter | Biotech Hunter